ASM Microbe 2016: PRO 140 Antibody Injections Maintain Viral Suppression Off ART


Subcutaneous injections of PRO 140, a monoclonal antibody that blocks HIV entry into cells, was well-tolerated and maintained undetectable viral load for more than a year after stopping antiretroviral therapy (ART) in patients with viral suppression, according to a study presented at the ASM Microbe 2016 meeting this week in Boston.

HIV uses 2 co-receptors -- CCR5 and CXCR4 -- along with the CD4 cell surface receptor to enter cells. PRO 140 is a humanized IgG4 monoclonal antibodythat works by blocking CCR5, thereby preventing HIV from getting into cells and replicating. About 70% of people with HIV in the U.S., and up to 90% of newly diagnosed people, have CCR5-tropic virus.

Previous studies showed that a single intravenous injection of PRO 140 dramatically reduced HIV levels, and weekly subcutaneous (under the skin) injections reduced viral load significantly more than placebo. Results to date suggest that PRO 140 does not negatively affect normal immune functions mediated by CCR5.

PRO 140 was initially developed by Progenics, but was acquired by CytoDyn in 2012. Clinical trial data on PRO 140 has not been presented at scientific conferences or in medical journals for several years, but CytoDyn has issued numerous press releases tracking its progress.

Paul Maddon, a scientific advisor at CytoDyn, presented findings from a Phase 2b trial of PRO 140 as maintenance therapy for people who had achieved viral suppression on standard combination ART.

The CD01 study included 39 HIV-positive adults with exclusively CCR5-tropic HIV (according to the Trofile DNA Co-receptor Tropism Assay), viral load below 40 copies/mL on a stable ART regimen, and a CD4 T-cell count above 350 cells/mm3. More than 90% were men with a median age of 55 years.

All participants in this open-label study switched, with 1 week of overlap, from their ART regimen to weekly 350 mg subcutaneous injections of PRO 140 monotherapy for up to 12 weeks. Those who experienced viral rebound restarted ART.

Among the 28 patients in the cohort assessing longer-term treatment, 15 people who maintained viral suppression for 12 weeks were trained to self-administer their shots and allowed to continue PRO 140 maintenance therapy for an additional 108 weeks in an extension phase. In this group 87% were men, 20% were non-white, the median age was 55, the median CD4 count was 586 cells/mm3, and they had been diagnosed with HIV for a median of 13 years.


"For >1 year, weekly PRO 140 subcutaneous 350 mg provided full viral suppression, was well tolerated, and enabled the avoidance of potential toxicity of ART while preserving drug options," the researchers concluded. "These results support further development of PRO 140 SC as a simple, long-acting, single-agent maintenance therapy after initial ART in selected HIV-1 patients."

They noted that the extension phase of the study is ongoing, with a plan to further extend PRO 140 monotherapy beyond 120 weeks for patients with continued viral suppression.



J Lalezari, K Dhody, U Kowalczyk, PJ Maddon, et al. PRO 140 SC Monotherapy Provides Long-term, Full Virologic Suppression in HIV Patients. ASM Microbe. June 16-20, 2016. Session 371.

Other Source

CytoDyn. ASM Microbe 2016 Presentation of Clinical Results From CytoDyn’s Phase 2b Monotherapy Extension Study Now Available. Press release. June 22, 2016.

CytoDyn. PRO 140: How it Combats HIV. YouTube. December 4, 2012.